ID: h-5d68a7d2
Hypothesis

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation.
🧬 Microglial TREM2🩺 connectomics🎯 Composite 53%💱 $0.53▼3.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 5 support 4 oppose
⚠ Missing Evidence⚠ Thin Description Senate Quality Gates →
Mechanistic 0.70 (15%) Evidence 0.65 (15%) Novelty 0.75 (12%) Feasibility 0.50 (12%) Impact 0.65 (12%) Druggability 0.55 (10%) Safety 0.40 (8%) Competition 0.55 (6%) Data Avail. 0.65 (5%) Reproducible 0.40 (5%) KG Connect 0.50 (8%) 0.535 composite

🧪 Overview

Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
    B["TREM2 Receptor<br/>Ligand Binding"]
    C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
    D["SYK Kinase<br/>Activation"]
    E["PLCG2<br/>IP3 + DAG Generation"]
    F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
    G["Microglial Phagocytosis<br/>Plaque Compaction"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix5 supports4 contradicts
Supports
TREM2 loss-of-function variants increase AD risk 2-4 fold
Supports
TREM2 is required for microglial response to amyloid plaques
Supports
TREM2 agonist promotes microglial clustering around plaques and reduces neurite dystrophy
Supports
Hub regions show heightened connectivity burden correlating with pathology
Supports
Synaptic loss in AD correlates with dysregulated microglial surveillance
Contradicts
AL002c (TREM2 agonist) failed to meet primary endpoint in INVOKE-2 Phase 2 trial (2024)
Contradicts
TREM2 deficiency reduces amyloid pathology in some contexts (reduced microglial clustering)
Contradicts
Microglial states in AD are heterogeneous - single pathway modulation insufficient
Contradicts
Mouse-to-human microglial translation limitations affect validity
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MICROGLIAL

No curated PDB or AlphaFold mapping for MICROGLIAL yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for Microglial TREM2 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Microglial TREM2 →

No DepMap CRISPR Chronos data found for Microglial TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0241
Events (7d)
3
Price History
▼3.4%

💾 Resource Usage

LLM Tokens
47,826
$0.1435
Total Cost
$0.1435

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we administer a selective TREM2 agonist (anti-TREM2 agonistic antibody at 10mg/kg, weekly ip) to 6-month-old 5xFAD mice for 8 weeks, THEN we will observe a significant reduction in cortical synapti≥20% reduction in excitatory synapse density (PSD-95/vGLUT1 puncta) in cortical layer 5 neurons in the agonist-treated group versus vehicle controls— no observation —pending0.65
IF we perform longitudinal in vivo two-photon microscopy to monitor dendritic spine turnover in Trem2^R47H knock-in mice crossed with Thy1-YFP reporters following a 4-week regimen of TREM2-activating Spine elimination rate increases to ≥0.05eliminations/hour with unchanged spine formation rate (<0.05/hour), yielding net spine density reduction of 15-25%— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we administer a selective TREM2 agonist (anti-TREM2 agonistic antibody at 10mg/kg, weekly ip) to 6-month-old 5xFAD mice for 8 weeks, THEN we will observe a significant reduction in cortical synaptic density (measured by PSD-95+ vGLUT1 colocalization via confocal microscopy) compared to vehicle-tr
Predicted outcome: ≥20% reduction in excitatory synapse density (PSD-95/vGLUT1 puncta) in cortical layer 5 neurons in the agonist-treated group versus vehicle controls
Falsification: No significant difference in synaptic density between TREM2 agonist and vehicle groups (p>0.05) OR paradoxical increase in synapse number, indicating impaired rather than enhanced pruning
pendingconf 58%
IF we perform longitudinal in vivo two-photon microscopy to monitor dendritic spine turnover in Trem2^R47H knock-in mice crossed with Thy1-YFP reporters following a 4-week regimen of TREM2-activating nanobodies (0.5mg/kg, biweekly), THEN we will observe increased spine elimination rate (≥30% elevati
Predicted outcome: Spine elimination rate increases to ≥0.05eliminations/hour with unchanged spine formation rate (<0.05/hour), yielding net spine density reduction of 1
Falsification: Spine elimination rate remains unchanged (<5% difference from baseline) or spine formation rate increases significantly, indicating TREM2 activation does not selectively enhance pruning
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.